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Abstract
Objective: Subjects with Polycystic ovarian syndrome (PCOS) are at increased risk of Type 2 diabetes mellitus (T2DM). The
mechanism of this enhanced risk is unclear. Circulating vascular progenitor cells (VPC) are immature bone marrow derived
cells capable of differentiating into mature endothelial cells. VPC number/function and central arterial stiffness predict
cardio-metabolic disease in at-risk populations.
Design: We studied VPC and arterial stiffness measures in non-obese PCOS subjects as compared to age and body mass
index (BMI) matched healthy controls in a cross–sectional study.
Methods: Fourteen subjects with PCOS and 12 controls of similar age, BMI (all ,30 kg/m
2) and metabolic profile were
studied. VPC number and in vitro function were studied by flow cytometry and tube formation assays respectively.
Augmentation index (AIx), a measure of central arterial stiffness, and central (aortic) blood pressures (BP) were measured by
applanation tonometry.
Results: Subjects with PCOS had a reduced number, mean6SEM, of circulating CD34
+133
+ VPCs (317.5651.0 vs.
558.36101.2, p=0.03) and impaired in vitro tube formation (completed tube area 1.060.06 vs. 1.260.05610
6 mm
2 p=0.02).
PCOS subjects had significantly higher AIx (18.461.9% vs. 4.962.0%) and this difference remained significant even after
adjustments for age, BMI and smoking (p=0.003) in multivariate analyses. Central systolic and pulse pressure were higher in
PCOS subjects but these differences were not statistically significant after adjustment for age. Brachial systolic and pulse
pressures were similar. VPC number/function and arterial stiffness or BP measures were not correlated.
Conclusions: Non-obese PCOS is characterized by a reduced VPC number, impaired VPC function and increased central
arterial stiffness. These changes in novel vascular risk markers may explain the enhanced risk of T2DM and CVD in PCOS.
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Introduction
The diagnosis of polycystic ovarian syndrome (PCOS) confers a
higher risk of type 2 diabetes mellitus (T2DM) and possibly
cardiovascular disease (CVD) which often becomes more pro-
nounced as subjects age (1). The pathophysiology of the enhanced
cardio-metabolic risk in PCOS is not fully explained by traditional
risk factors [1]. CVD and T2DM may share a common
pathophysiology as proposed in the ‘common soil’ hypothesis with
data indicating that both are vascular conditions [2]. Circulating
vascular progenitor cells (VPC) are a subset of mononuclear cells
derived from the bone marrow [3] that retain the ability to
proliferate and differentiate into mature endothelial cells which
contribute to vessel homeostasis and repair. Of interest progressive
deficit in VPC number/function contributes to the development of
atherosclerosis and associates with impaired glucose metabolism
including T2DM [4]. Central arterial stiffness, a hallmark of
vascular ageing, is an independent predictor of CVD and associates
with risk of T2DM [5–7]. Augmentation index (AIx) is a validated
measure of central arterial stiffness and central aortic pressure
changes predict adverse CVD outcomes in at risk populations
independent of brachial blood pressure [6],[7]. Obesity per se
reduces VPC number/function, increases arterial stiffness and
enhances risk of CVD and T2DM in PCOS [1],[7–9].
Whether there are differences in VPC and central aortic
pressures, two emerging vascular bio-markers of cardio-metabolic
risk, in non-obese PCOS subjects is unknown.
Results
Fourteen subjects with PCOS and 12 healthy controls were
studied. More than 2/3rds of subjects in each group were
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control) was similar. The clinical and biochemical characteristics’
of PCOS subjects and healthy controls are shown in Table 1.
There was no statistically significant difference between the PCOS
vs. control group, in age, weight, BMI and waist circumference
(Table 1). All patients had a BMI,30 kg/m
2 and were
normotensive [brachial systolic (SBP) and diastolic blood pressure
(DBP) ,130/90 mmHg respectively]. Total cholesterol, mean6
standard error of the mean, (4.660.2 vs. 4.060.1 mmol/l
p=0.055), plasma triglycerides (1.060.1 vs. 0.760.1 mmol/l
p=0.055) were higher in the PCOS group. Serum total
testosterone was 27% higher in PCOS but this difference did
not reach conventional statistical significance (2.660.3 vs. 1.960.2
p=0.06). Fasting plasma glucose (4.760.1 vs. 4.560.1 mmol/l
p=0.2) did not differ between the two groups. Insulin resistance
estimated by HOMA was higher (nearly 36%) in the PCOS group
(2.560.4 vs. control 1.660.3) but this difference was not
significant (p=0.2). Of note all subjects had fasting plasma glucose
,6.0 mmol/l.
PCOS subjects had an almost a three fold higher AIx. Mean
brachial arterial blood pressure (a measure of the passive
distension of the arterial wall), brachial SBP and pulse pressures
were not elevated and similar in both groups (Table 1).
As age and smoking can affect circulatory parameters,
univariate correlations of AIx, central arterial pressures and
CD34+CD133+ VPC number with PCOS diagnosis, age and
smoking were performed (Table 2). These analyses showed a
statistically significant correlation between AIx and PCOS and
between AIx and age. There was no significant association
between AIx and smoking. Similar results were observed for
central aortic SBP and pulse pressure (Table 2). In univariate
analyses BMI was not significantly associated with AIx, central
aortic blood pressures and VPC number or function.
In a multivariate regression analysis model with AIx as the
dependent variable, PCOS emerged as the most important factor
followed by age (Table 3). The results of these analyses show that
PCOS subjects independent of age, BMI and smoking status have
significantly greater central arterial stiffness as determined by AIx.
The results of the model suggests that PCOS subjects have nearly
11% greater AIx than controls independent of age which is
equivalent to almost 10 years of vascular ageing [10]. The adjusted
R
2 value from this model suggests that 55% of the variance of AIx
is predicted by PCOS and age. In independent samples (unpaired)
t-tests analyses, PCOS subjects had higher central aortic systolic
blood pressure (103.762.4 vs. 94.962.2 mmHg p=0.03), central
aortic diastolic blood pressure (75.661.8 vs. 69.762.4 mmHg
p=0.08), central aortic pulse pressure (28.261.0 vs. 25.161.1
p=0.04). However these differences were not statistically signif-
icant after adjustment for age. When central aortic SBP was
entered as the dependent variable, the multivariate regression
model results indicated that PCOS independent of age, BMI and
smoking does have some effect albeit not reaching conventional
statistical significance (PCOS unstandardized coefficient B 8.23, p
value=0.09. We did not observe a statistically significant effect of
PCOS, independent of age, BMI and smoking, on central aortic
pulse pressure when the latter was entered as the dependent
variable in a multivariate regression model.
Subjects with PCOS had a significantly lower number of
circulating CD34
+133
+ VPC, 317.5651.0 vs. 558.36101.2, per
10
6 lymphomonocyte events p=0.03 (Figure 1a). PCOS subjects
also had lower number CD34
+ cells (697.56114.5 vs.
929.96149.3p=0.2). CD34
+CD133
+KDR
+ and CD34
+KDR
+
cells per 10
6 lymphomonocyte events were very small in both
groups with no statistically significant differences noted between
PCOS subjects and healthy controls. Age and smoking status were
not significantly associated with CD34+CD133+ VPC number in
univariate correlation analyses (Table 2). VPC functional assays
were performed in 10 PCOS and 8 control consecutive patients
from the population described comparable for all characteristics.
The phenotype of VPC cultured for 7 days and 14 days did not
differ between the groups however day 14 VPC were characterised
by greater expression of endothelial markers such as von
Willebrand factor, CD31 and eNOS compared to day 7 VPC
which expressed predominantly white cell markers such as CD14
as previously reported [11]. Migration and tube formation assays
with VPC cultured for 7 days showed similar results in both groups
(data not shown). VPC cultured for 14 days from PCOS subjects
had less migration (22,5536589 vs. 25,06261523) but this
difference did not reach statistical significance (p=0.23). However
VPC cultured for 14 days from PCOS subjects showed a
significantly reduced completed tube area (1.060.06 vs.
1.260.05610
6 mm
2 p=0.02) with VEGF-A compared to controls
(Figure 1b and Figure 2).
Table 1. Selected clinical, biochemical and brachial blood pressure measurements in non-obese subjects with PCOS and age and
body mass index matched healthy controls.
PCOS Controls P value
n=14 n=12
Age (years) 26.461.0 23.261.5 0.08
Body mass index (Kg/m
2) 24.260.8 23.060.7 0.26
Weight (kg) 65.963.1 61.061.2 0.21
Waist circumference (cm) 86.362.5 82.161.8 0.22
Brachial systolic blood pressure (mmHg) 115.263.4 108.763.0 0.17
Brachial diastolic blood pressure (mmHg) 76.262.6 68.162.6 0.05
Brachial pulse pressure (mmHg) 38.961.0 40.061.8 0.60
Brachial mean arterial pressure (mmHg) 89.262.9 82.062.6 0.08
Augmentation Index % corrected for heart
rate of 75 beats per minute
18.461.9 4.962.0 0.001*
Data are presented as mean6SEM.
doi:10.1371/journal.pone.0020317.t001
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This is the first study demonstrating a lower circulating number
and impaired function of VPC in PCOS. PCOS subjects had
significantly lower number of CD34
+133
+ cells, which are early
VPC capable of differentiating into endothelial cells in the setting
of vascular inflammation or injury, and are central to repair of
damaged endothelia [12],[13]. We also report, after adjustment
for age and BMI, significantly greater central arterial stiffness in
non-obese PCOS subjects as compared to matched controls
despite similar brachial and central blood pressures a finding not
previously demonstrated. Our results suggest that PCOS subjects
independent of age and smoking status have almost a 10 year
increase in vascular ageing [10].
In-vitro measures of VPC function in PCOS have not
previously been reported. Tube formation was significantly
reduced only in VPC cultured for 14 days from PCOS subjects
suggesting impaired vascular repair. The characteristics/pheno-
type of cells cultured for 7 and 14 days did not differ between
PCOS and controls, however VPC cultured for 14 days expressed
predominantly endothelial markers and this may explain the VPC
function results observed [11].
Our results may explain at least in part the pathophysiological
mechanism of endothelial dysfunction in PCOS which is not fully
explained by traditional cardio-metabolic risk factors [14]. In
contrast to our findings, a recent study demonstrated no difference
in CD34
+133
+ cell number between PCOS and controls. In this
study subjects were older, included obese cases and controls and
subjects with PCOS were not selected on the basis of menstrual
irregularity [15]. In a recent large cross-sectional study of 425
subjects categorised according to carbohydrate metabolism status,
a reduction in the number of VPC marked the clinical onset of
T2DM, independent of other known risk factors [4]. The authors
of this study proposed that defective mobilisation and increased
apoptosis of VPC may account for these results [4] although the
exact mechanism(s) by which reductions in the number and
function of VPC result in an increased risk of T2DM remains
unclear. The number of CD34
+133
+ cells has been found to be
reduced in patients with essential hypertension when compared to
normotensive individuals [16]. However we did not observe any
correlation between brachial and central arterial pressures and
VPC numbers or function which suggests that the changes in VPC
and arterial stiffness are potentially independently associated with
the ‘enhanced vascular risk milieu’ that characterises PCOS. VPC
number has been reported to vary depending on timing of
menstrual cycles, but the literature is discordant in that some
authors report higher VPC numbers in the follicular phase whilst
others report higher numbers in the luteal phase [17],[18].
Moreover Fadini et al did not observe difference between follicular
and luteal phases of the cycle but did note an increase in VPC
during ovulation [19]. Lemieux et al have also reported a similar
pre-ovulatory surge in VPC numbers but no difference in numbers
between menstrual and mid luteal phases of the menstrual cycle
[20]. Interestingly VPC function does not appear to be affected by
the timing/phase of the menstrual cycle [17].
Recent evidence is that central arterial stiffness and blood
pressures may be more clinically relevant than peripheral
(brachial) pressures for the pathogenesis of CVD and T2DM
Table 2. Univariate correlations of AIx, central arterial pressures, and CD34+CD133+ VPC number with PCOS diagnosis, age and
smoking.
Augmentation Index as dependent variable Coefficient of correlation r value Significance p value
PCOS 0.65 0.01*
Age 0.60 0.02*
Smoking 0.31 0.13
Central aortic systolic blood pressure as the dependent variable
PCOS 0.45 0.03*
Age 0.42 0.04*
Smoking 0.27 0.20
Central aortic pulse pressure as the dependent variable
PCOS 0.46 0.02*
Age 0.44 0.03*
Smoking 0.38 0.06
CD34+CD133+ VPC number as the dependent variable
PCOS 20.50 0.01*
Age 20.28 0.20
Smoking 20.30 0.14
doi:10.1371/journal.pone.0020317.t002
Table 3. Age and BMI independent effects of PCOS on central
arterial stiffness, as measured by augmentation index.
Variable Unstandardized Coefficient B Significance p value
PCOS 11.04 0.003
Age 0.86 0.015
BMI 0.08 0.885
Subjects were 12 healthy controls and 14 subjects with PCOS matched for body
mass index.
doi:10.1371/journal.pone.0020317.t003
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PCOS subjects compared to controls but no significant difference
between lean PCOS (BMI,25 kg/m
2) and controls [15]. In our
study, waist circumference, a clinically proven measure of central
obesity and associated cardiovascular risk, was not significantly
different between control and PCOS subjects. This suggests that
central obesity is unlikely to be the most important cause of the
increased arterial stiffness observed in PCOS. The literature in this
area is conflicting with some studies reporting that central obesity,
rather than PCOS per se, is associated with increased arterial
stiffness and others reporting that obese and non-obese PCOS
subjects have greater arterial stiffness compared to matched
controls [9],[21],[22]. Soares et al reported increases in arterial
stiffness in PCOS in the absence of obesity and hypertension in
non-obese PCOS (mean BMI 22.7) subjects as compared to
matched healthy controls [21]. In contrast there are reports that
non-obese PCOS subjects do not have greater arterial stiffness as
compared to matched controls [15],[23]. Kelly et al in their
seminal paper in this field reported that obese PCOS subjects
(mean BMI 33.2) had greater arterial stiffness that controls with
similar BMI and waist hip ratio [22].
Vascular ageing is characterized by the loss of elasticity in the
wall of the aorta and as a consequence there is increased central
arterial (aortic) stiffness. This results in the faster return of pressure
waves from distal sites (resistance vessels) where impedance
mismatch occurs, which shifts augmentation of blood pressure
from diastole to systole resulting in elevated central SBP and AIx.
The value of arterial stiffness as a therapeutic target in PCOS was
Figure 1. Circulating vascular progenitor cell (VPC) number (A) and in-vitro function (B) in healthy controls (%) and PCOS (&)
subjects. Circulating CD34
+/CD133
+ VPC number is reduced (A) and VPC function impaired (B) in PCOS patients vs. healthy control. (* p=0.03,
** p=0.02). Data are presented as mean6SEM. For A, PCOS n=14 vs. control n=12, for B PCOS n=10 vs. control n=8.
doi:10.1371/journal.pone.0020317.g001
Figure 2. Tubule formation assay in healthy controls (A) and PCOS (B) patients. Panels A and B are representative pictures of the tubule
network formed by the VPC (white dots) and HUVECs. The white line represents the surface area which was measured i.e. area formed by complete
closed tubes.
doi:10.1371/journal.pone.0020317.g002
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central blood pressures with metformin [24]. Our study was cross-
sectional proof of concept study and therefore larger prospective
studies are required to clarify if the differences in arterial stiffness,
VPC number and function are a cause or an effect of PCOS and
to determine the long term consequences of these changes. In
conclusion, we have demonstrated the novel findings of reduced
number and function of VPC, raised central aortic blood pressures
and arterial stiffness despite similar ‘normal’ brachial blood
pressures in PCOS subjects compared to matched healthy
controls. Our results highlight the need for larger confirmatory
studies to evaluate if these differences in emerging predictors of
cardio-metabolic disease explain, at least in part, the enhanced risk
of T2DM and CVD in PCOS.
Materials and Methods
Ethics statement
The study was approved by the research ethics committee of
Guy’s and St. Thomas’ Hospitals and was undertaken in
adherence to the Declaration of Helsinki. Written consent was
obtained from all patients who participated to this study.
Inclusion/exclusion criteria and subject characteristics: Subjects
with a confirmed diagnosis of PCOS by the Rotterdam Criteria
[25] who were not on any medication and attending the endocrine
clinics at Guy’s and St Thomas’ Hospital London were studied. All
PCOS subjects had a history of irregular/infrequent menstrual
cycles and polycystic ovaries, as defined by ultrasonography (the
presence of 12 or more follicles in each ovary measuring 2 to
9 mm in diameter, and/or ovarian volume .10 mL). Further-
more all PCOS subjects had a clinical history and clinical signs of
hyperandrogenaemia (hirsuitism and acne) that fulfilled the
Rotterdam diagnostic criteria. The participants of the consensus
group the defined the Rotterdam criteria suggest that the primary
clinical indicator of androgen excess is the presence of hirsuitism
and that the presence of acne is a marker for hyperandrogenism
particularly in patients with irregular menses [25]. A limitation of
our study was that hirsuitism was not scored by the Ferriman-
Gallwey score.
Exclusion criteria included a history of T2DM, other endocrine
illnesses (e.g.thyroid disease, adrenal disease, pituitary disease),
CVD and hypertension. All controls were healthy with no clinical
or biochemical features/characteristics of PCOS and had regular
menstrual cycles. Control subjects were not on any medications
and had measurements performed in the follicular phase of the
menstrual cycle.
Central aortic blood pressure and AIx were measured by
applanation tonometry (Millar tonometer, Millar Instruments,
Houston, TX) using the Sphygmocor system (Atcor, Sydney,
Australia) at the radial artery as previously described [26]. AIx is
calculated as the ratio of the augmentation pressure (AP) that
results in the amplification of peak systolic blood pressure over the
pulse pressure (PP) (AIx=AP/PP) and corrected for heart rate of
75 beats per minute [6],[7],[26]. Brachial blood pressure was
measured in the dominant arm with the subject seated after a five-
minute rest using an automated sphygmomanometer (Dinamap-
8100T, GE-Medical, Slough, UK). The mean of three consecutive
measurements was used for AIx, brachial and central blood
pressure measures. Weight, height and waist circumference were
measured using standard methodology as previously described
[26]. Total cholesterol, plasma glucose as previously described
[26], serum testosterone (competitive electro-chemiluminescent
immunoassay, Testosterone II cobas
R Roche E170, Roche
Diagnostics GmbH, Mannheim, Germany) and insulin (electro-
chemiluminescent immunoassay Insulin cobas
R Roche
Elecsys2010 Roche Diagnostics GmbH, Mannheim, Germany)
were measured after an overnight fast. Insulin resistance was
estimated using the homeostasis model assessment of insulin
resistance (HOMA-IR) and calculated as fasting insulin x fasting
glucose/22.5 [27]. T2DM and impaired fasting glycaemia was
excluded by fasting plasma glucose levels ,7 mmol/l and
,6 mmol/l respectively and no previous history of symptoms of
hyperglycemia and or casual plasma glucose $11.1 mmol/l [28].
Circulating VPC were isolated and cultured as follows.
Mononuclear cells (MNCs) were isolated from 40 ml peripheral
blood from healthy or PCOS subjects by density gradient
centrifugation with Ficoll Paque PLUS (density 1.077 g/ml; GE
Healthcare) according to manufacturer recommendations. MNCs
(10610
6) were plated in 2 ml endothelial growth medium (EGM-
2 MV bulletkit; Lonza), on fibronectin-coated six-well plates at
37uC in a 5% CO2 humidified incubator. Under daily
observation, after 4 days of culturing, medium were changed
and non-adherent cells removed. Adherent VPC at 7 days of
culture appear elongated and spindle shaped. Thereafter, medium
were replaced every 3 days, and cell differentiation followed for 14
days in total.
Circulating VPC were characterized and counted by flow
cytometry and immunofluorescence as previously described [11].
Briefly, leukocytes were isolated from peripheral blood after red
cells lysis with ammonium chloride buffer. Following Fc receptor
blocking (FC blocker - Miltenyl Biotec, Bergisch Gladbach,
Germany) cells were labelled with CD133-PE, CD34-FITC
(Miltenyl Biotec, Bergisch Gladbach, Germany) and VEGFR-
APC (R&D System, Abondgon, UK) antibodies on ice in the dark
following manufacturer instructions. Cells were fixed using BD
lysing solution and acquired using a flow cytometer- the FACS
Calibur analyser (FACS Calibur; BD Sciences, Franklin Lakes, NJ,
USA). At least 500 CD34
+133
+ events were collected for each
subject and typically showed more than 1610
6 events in the
lymphomonocytes gated area.
Prior to performing functional assays, circulating VPC from
healthy and PCOS subjects were characterised by immunofluo-
rescence as previously described [11]. Human umbilical vascular
endothelial cells and macrophage line U937 were used as positive
control for endothelial and monocytic markers respectively,
negative control was included by omitting the first antiserum.
Non-specific Fc receptors were blocked using blocking buffer (CAS
block, Zymed laboratories-Invitrogen, Paisley, UK). Primary
antisera (Santa Cruz Biotechnology, SantaCruz, CA, USA) and
secondary AlexaFluor488 or Texas Red antisera were used at 1/
50 dilution (ChemMate
TM Antibody Diluent, Dako, Ely, UK).
Cells were stained in duplicate, and four different fields (,20–
30 cells) were assessed by a blinded investigator. At 7 days culture,
cells expressed mainly VEGFR2, eNOS, CD45 and CD14. At 14
days culture, cells expressed more endothelial specific markers
(VEGFR2, CD144, Von Willebrand Factor-VWF, CD31, and
eNOS) while a reduction in cells positive for CD14 was observed
as previously described [11]. Most cells expressed CD45 at 14 days
in both groups. Stem cell markers CD34 and CD133 were positive
in a small proportion of cells.
Circulating VPC functional assays were performed as previously
described in 10 PCOS subject and 8 controls using 7-days and 14-
days cultured VPC in the presence and absence of Vascular
Endothelial Growth Factor (VEGF)-A [11,12].
Statistical analyses
All measurements were performed blinded to group allocation.
The primary aim/endpoint of the study was to evaluate if there
Arterial Stiffness and Progenitor Cells in PCOS
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subjects and age and BMI matched healthy controls. As this was a
proof of concept study no formal power calculation was
performed. Shapiro-Wilk test was used to test if the distribution
of the variable was normal. HOMA-IR, CD34
+ cells, CD34
+133
+
cell numbers were skewed, and log transformation of data resulted
in a normal distribution. Comparisons between PCOS and control
group of variables which were normally distributed was made
using the unpaired (independent samples) Student’s t-test.
CD34
+CD133
+KDR
+ and CD34
+KDR
+ cell counts were not
normally distributed and differences between groups were tested
by the Kruskall-Wallis test. As age, BMI and smoking may affect
circulatory parameters, univariate regression analysis appropriate
for the normal (Pearson’s correlation) or not normal distribution
(Spearman’s correlation) of the variable was performed to test for
associations of AIx, central arterial pressures and CD34+CD133+
VPC number with smoking, age, BMI and PCOS diagnosis.
Correlations which were significant at less than the 10% level
were entered in a multiple regression model with AIx, central
aortic systolic blood pressure and central aortic pulse pressure as
the dependent variable, to determine which variables indepen-
dently best predicted circulatory parameters. All analyses were
performed with SPPS version 15.0. p,0.05 was taken as
indicating statistical significance, and all tests were 2-tailed.
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